Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Unternehmen & Branche
| Name | RECURSION PHARMACEUTICALS, INC. |
|---|---|
| Ticker | RXRX |
| CIK | 0001601830 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,53 Mrd. USD |
| Beta | 1,01 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 74,681,000 | -644,759,000 | -1.44 | 1,474,130,000 | 1,130,865,000 |
| 2025-09-30 | 10-Q | 5,175,000 | -162,253,000 | -0.36 | 1,399,526,000 | 1,046,948,000 |
| 2025-06-30 | 10-Q | 19,223,000 | -171,897,000 | -0.41 | 1,302,355,000 | 919,146,000 |
| 2025-03-31 | 10-Q | 14,745,000 | -202,487,000 | -0.50 | 1,305,234,000 | 933,947,000 |
| 2024-12-31 | 10-K | 58,839,000 | -463,661,000 | -1.69 | 1,448,598,000 | 1,034,782,000 |
| 2024-09-30 | 10-Q | 26,082,000 | -95,842,000 | -0.34 | 726,499,000 | 524,559,000 |
| 2024-06-30 | 10-Q | 14,417,000 | -97,540,000 | -0.40 | 775,861,000 | 584,449,000 |
| 2024-03-31 | 10-Q | 13,794,000 | -91,373,000 | -0.39 | 557,847,000 | 401,151,000 |
| 2023-12-31 | 10-K | 44,575,000 | -328,066,000 | -1.58 | 653,699,000 | 463,436,000 |
| 2023-09-30 | 10-Q | 10,533,000 | -93,017,000 | -0.43 | 630,825,000 | 437,967,000 |
| 2023-06-30 | 10-Q | 11,017,000 | -76,726,000 | -0.38 | 666,699,000 | 468,963,000 |
| 2023-03-31 | 10-Q | 12,134,000 | -65,327,000 | -0.34 | 627,366,000 | 430,175,000 |
| 2022-12-31 | 10-K | 39,843,000 | -239,476,000 | -1.36 | 701,288,000 | 485,806,000 |
| 2022-09-30 | 10-Q | 13,160,000 | -60,445,000 | -0.35 | 611,533,000 | 388,034,000 |
| 2022-06-30 | 10-Q | 7,674,000 | -65,560,000 | -0.38 | 672,515,000 | 437,579,000 |
| 2022-03-31 | 10-Q | 5,333,000 | -55,979,000 | -0.33 | 734,319,000 | 493,566,000 |
| 2021-12-31 | 10-K | 10,178,000 | -186,479,000 | -1.49 | 610,345,000 | 542,938,000 |
| 2021-09-30 | 10-Q | 2,534,000 | -47,428,000 | -0.28 | 658,606,000 | 599,032,000 |
| 2021-06-30 | 10-Q | 2,549,000 | -43,401,000 | -0.31 | 698,590,000 | 642,714,000 |
| 2021-03-31 | 10-Q | 2,562,000 | -30,717,000 | -1.33 | 271,943,000 | -233,031,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Gibson Christopher | Director | Open Market Sale | -40,000 | 3.61 | -144,400.00 | -33,5% | |
| 2026-04-07 | Gibson Christopher | Director | Open Market Sale | -40,000 | 3.10 | -124,000.00 | -28,8% | |
| 2026-03-23 | Gibson Christopher | Director | Open Market Sale | -40,000 | 3.25 | -130,000.00 | -30,2% | |
| 2026-03-09 | Khan Najat | Director, Officer, CEO and President | Open Market Sale | -28,298 | 3.35 | -94,659.64 | -22,0% | |
| 2026-03-03 | Borgeson Blake | Director | Open Market Sale | -170,000 | 3.46 | -588,200.00 | -136,5% | |
| 2026-02-19 | Gibson Christopher | Director | Open Market Sale | -40,000 | 3.46 | -138,400.00 | -32,1% | |
| 2026-02-18 | Taylor Ben R | Officer, Chief Financial Officer | Open Market Sale | -13,426 | 3.08 | -41,352.08 | -9,6% | |
| 2026-02-04 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.12 | -164,800.00 | -38,2% | |
| 2026-02-03 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.20 | -924,000.00 | -214,4% | |
| 2026-01-20 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.47 | -178,800.00 | -41,5% | |
| 2026-01-06 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.36 | -959,200.00 | -222,5% | |
| 2026-01-05 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.25 | -170,000.00 | -39,4% | |
| 2025-12-29 | Taylor Ben R | Officer, Chief Financial Officer | Open Market Sale | -21,383 | 4.18 | -89,380.94 | -20,7% | |
| 2025-12-22 | Khan Najat | Director, Officer, Chief R&D Commercial Officer | Open Market Sale | -124,403 | 4.41 | -548,592.35 | -127,3% | |
| 2025-12-19 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.50 | -180,000.00 | -41,8% | |
| 2025-12-04 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.63 | -185,200.00 | -43,0% | |
| 2025-12-02 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.37 | -961,400.00 | -223,1% | |
| 2025-11-19 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.16 | -166,400.00 | -38,6% | |
| 2025-11-04 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 5.21 | -208,400.00 | -48,4% | |
| 2025-10-23 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 5.70 | -570,000.00 | -132,2% | |
| 2025-10-10 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 6.04 | -604,000.00 | -140,1% | |
| 2025-09-25 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.76 | -476,000.00 | -110,4% | |
| 2025-09-10 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.71 | -471,000.00 | -109,3% | |
| 2025-08-26 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.84 | -484,000.00 | -112,3% | |
| 2025-08-18 | Khan Najat | Director, Officer, Chief R&D Commercial Officer | Open Market Sale | -36,599 | 5.52 | -202,172.88 | -46,9% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 5.28 | -528,000.00 | -122,5% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -500,300 | 5.28 | -2,641,584.00 | -612,9% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -17,875 | 5.28 | -94,380.00 | -21,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.